## **Core Concept**
Von Willebrand Disease (VWD) is a common inherited bleeding disorder caused by deficiency or dysfunction of **von Willebrand factor (VWF)**, which plays a critical role in platelet adhesion and stabilization of **factor VIII**. Management of VWD involves replacement of VWF and/or factor VIII.

## **Why the Correct Answer is Right**
Desmopressin (DDAVP) is a synthetic analogue of vasopressin that increases the release of VWF and factor VIII from storage sites into the bloodstream. It is often used as a first-line treatment for mild to moderate VWD, especially for patients with a history of bleeding. In this case, the patient has mild VWD and a history of bleeding during previous surgery, making DDAVP a suitable choice for prophylaxis before dental extraction.

## **Why Each Wrong Option is Incorrect**
* **Option A:** Tranexamic acid is an antifibrinolytic agent that can be used to prevent excessive bleeding but does not address the underlying deficiency of VWF and factor VIII in VWD. It is often used as an adjunct therapy rather than a prophylactic measure for surgical procedures in patients with VWD.
* **Option B:** Fresh frozen plasma (FFP) contains VWF and factor VIII but is not the preferred choice for prophylaxis due to the risk of volume overload and the availability of more concentrated and safer products like desmopressin or VWF concentrates.
* **Option C:** This option is not provided, but presumably, it could be another incorrect choice.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that desmopressin is effective in patients with mild to moderate VWD who have a responsive phenotype (i.e., they respond to DDAVP with an increase in VWF and factor VIII levels). Not all patients with VWD are responsive, so it's crucial to test the response before using it as a prophylactic measure.

## **Correct Answer:** D. Desmopressin.